ATE278419T1 - Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a - Google Patents

Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a

Info

Publication number
ATE278419T1
ATE278419T1 AT98915239T AT98915239T ATE278419T1 AT E278419 T1 ATE278419 T1 AT E278419T1 AT 98915239 T AT98915239 T AT 98915239T AT 98915239 T AT98915239 T AT 98915239T AT E278419 T1 ATE278419 T1 AT E278419T1
Authority
AT
Austria
Prior art keywords
surfactant
lipid
derivative
attenuated
monophosphoryl lipid
Prior art date
Application number
AT98915239T
Other languages
English (en)
Inventor
R Thomas Crane
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Application granted granted Critical
Publication of ATE278419T1 publication Critical patent/ATE278419T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT98915239T 1997-04-01 1998-04-01 Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a ATE278419T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83107397A 1997-04-01 1997-04-01
PCT/US1998/006528 WO1998043670A2 (en) 1997-04-01 1998-04-01 Aqueous immunologic adjuvant compositions of monophosphoryl lipid a

Publications (1)

Publication Number Publication Date
ATE278419T1 true ATE278419T1 (de) 2004-10-15

Family

ID=25258229

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98915239T ATE278419T1 (de) 1997-04-01 1998-04-01 Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a

Country Status (19)

Country Link
EP (1) EP0971739B1 (de)
JP (1) JP5019494B2 (de)
KR (1) KR100603884B1 (de)
CN (2) CN1259052A (de)
AT (1) ATE278419T1 (de)
AU (1) AU743114B2 (de)
BR (1) BR9811262A (de)
CA (1) CA2284586C (de)
DE (1) DE69826842T2 (de)
ES (1) ES2227825T3 (de)
HK (1) HK1026613A1 (de)
HU (1) HUP0001403A3 (de)
IL (2) IL132126A0 (de)
NO (1) NO994760L (de)
NZ (1) NZ338101A (de)
PL (1) PL190237B1 (de)
PT (1) PT971739E (de)
TR (1) TR199902437T2 (de)
WO (1) WO1998043670A2 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
PL211151B1 (pl) 2000-10-18 2012-04-30 Glaxosmithkline Biolog Sa Kompozycja immunogenna oraz zastosowanie połączenia saponiny, oligonukleotydu immunostymulującego i lipopolisacharydu
DE60239594D1 (de) 2001-02-23 2011-05-12 Glaxosmithkline Biolog Sa Influenza vakzinzusammensetzungen zur intradermaler verabreichung
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
WO2006065139A2 (en) * 2004-12-17 2006-06-22 Nvi Nederlands Vaccininstituut Deacylation of lps in gram negative bacteria
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
CN106390108B (zh) 2005-04-29 2020-09-08 葛兰素史密丝克莱恩生物有限公司 用于预防或治疗结核分枝杆菌感染的新方法
NZ565512A (en) * 2005-08-02 2011-08-26 Novartis Vaccines & Diagnostic Reducing interference between oil-containing adjuvants and surfactant-containing antigens
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8018440B2 (en) 2005-12-30 2011-09-13 Microsoft Corporation Unintentional touch rejection
PT2468300T (pt) 2006-09-26 2018-01-30 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8836648B2 (en) 2009-05-27 2014-09-16 Microsoft Corporation Touch pull-in gesture
DK2437753T3 (en) 2009-06-05 2016-12-19 Infectious Disease Res Inst Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
FR2954703B1 (fr) 2009-12-28 2013-12-13 Chu Nantes Agonistes des recepteurs tlr 4 et 9 pour prevenir les complications septiques de l'immunodepression post-traumatique chez les patients hospitalises pour traumatismes severes
US8261213B2 (en) 2010-01-28 2012-09-04 Microsoft Corporation Brush, carbon-copy, and fill gestures
US9411504B2 (en) 2010-01-28 2016-08-09 Microsoft Technology Licensing, Llc Copy and staple gestures
US9519356B2 (en) 2010-02-04 2016-12-13 Microsoft Technology Licensing, Llc Link gestures
US9367205B2 (en) 2010-02-19 2016-06-14 Microsoft Technolgoy Licensing, Llc Radial menus with bezel gestures
US9310994B2 (en) 2010-02-19 2016-04-12 Microsoft Technology Licensing, Llc Use of bezel as an input mechanism
US8799827B2 (en) 2010-02-19 2014-08-05 Microsoft Corporation Page manipulations using on and off-screen gestures
US8751970B2 (en) 2010-02-25 2014-06-10 Microsoft Corporation Multi-screen synchronous slide gesture
US9075522B2 (en) 2010-02-25 2015-07-07 Microsoft Technology Licensing, Llc Multi-screen bookmark hold gesture
US8707174B2 (en) 2010-02-25 2014-04-22 Microsoft Corporation Multi-screen hold and page-flip gesture
US9454304B2 (en) 2010-02-25 2016-09-27 Microsoft Technology Licensing, Llc Multi-screen dual tap gesture
US8689123B2 (en) 2010-12-23 2014-04-01 Microsoft Corporation Application reporting in an application-selectable user interface
US8612874B2 (en) 2010-12-23 2013-12-17 Microsoft Corporation Presenting an application change through a tile
US9423951B2 (en) 2010-12-31 2016-08-23 Microsoft Technology Licensing, Llc Content-based snap point
US9383917B2 (en) 2011-03-28 2016-07-05 Microsoft Technology Licensing, Llc Predictive tiling
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
CA2832307A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US9104307B2 (en) 2011-05-27 2015-08-11 Microsoft Technology Licensing, Llc Multi-application environment
US9658766B2 (en) 2011-05-27 2017-05-23 Microsoft Technology Licensing, Llc Edge gesture
US9158445B2 (en) 2011-05-27 2015-10-13 Microsoft Technology Licensing, Llc Managing an immersive interface in a multi-application immersive environment
US9104440B2 (en) 2011-05-27 2015-08-11 Microsoft Technology Licensing, Llc Multi-application environment
US9557909B2 (en) 2011-09-09 2017-01-31 Microsoft Technology Licensing, Llc Semantic zoom linguistic helpers
US9146670B2 (en) 2011-09-10 2015-09-29 Microsoft Technology Licensing, Llc Progressively indicating new content in an application-selectable user interface
US9244802B2 (en) 2011-09-10 2016-01-26 Microsoft Technology Licensing, Llc Resource user interface
US20150190501A1 (en) 2011-09-12 2015-07-09 Imperial Innovations Limited Methods and compositions for raising an immune response to hiv
EP2850431B1 (de) 2012-05-16 2018-04-18 Immune Design Corp. Impfstoffe gegen hsv-2
EP2666785A1 (de) 2012-05-23 2013-11-27 Affiris AG Auf Komplementfaktor C5a basierender Impfstoff
EP2703483A1 (de) 2012-08-29 2014-03-05 Affiris AG PCSK9 Peptidimpfstoff
US10232035B2 (en) 2012-09-14 2019-03-19 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes virus and use thereof in vaccines
US9582122B2 (en) 2012-11-12 2017-02-28 Microsoft Technology Licensing, Llc Touch-sensitive bezel techniques
CA2909221A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US9477337B2 (en) 2014-03-14 2016-10-25 Microsoft Technology Licensing, Llc Conductive trace routing for display and bezel sensors
SI3122378T1 (sl) * 2014-03-26 2020-03-31 Glaxosmithkline Biologicals S.A. Mutantni stafilokokni antigeni
EP3169699A4 (de) 2014-07-18 2018-06-20 The University of Washington Krebsimpfstoffzusammensetzungen und verfahren zur verwendung davon
EP3138579A1 (de) 2015-09-05 2017-03-08 Biomay Ag Fusionsprotein zur behandlung einer infektion durch einen hepatitis-b-virus
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
EP3295956A1 (de) 2016-09-20 2018-03-21 Biomay Ag Polypeptidkonstrukt mit fragmenten von allergenen
CN111315406A (zh) 2017-09-08 2020-06-19 传染病研究所 包括皂苷的脂质体调配物及其使用方法
WO2019175147A1 (en) 2018-03-12 2019-09-19 Janssen Vaccines & Prevention B.V. Vaccines against intra-abdominal infections
EP3569612A1 (de) 2018-05-18 2019-11-20 Biomay Ag Behandlung und prävention von hausstaubmilbenallergien
AR118388A1 (es) 2019-03-18 2021-09-29 Janssen Pharmaceuticals Inc Bioconjugados de antígenos-polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos
KR102574882B1 (ko) 2019-03-18 2023-09-04 얀센 파마슈티칼즈, 인코포레이티드 대장균 o-항원 다당류의 바이오컨쥬게이트의 생성 방법, 이의 조성물 및 이의 사용 방법
CA3155424A1 (en) 2019-10-02 2021-04-08 Janssen Vaccines & Prevention B.V. Staphylococcus peptides and methods of use
WO2021144369A1 (en) 2020-01-16 2021-07-22 Janssen Pharmaceuticals, Inc. Fimh mutant, compositions therewith and use thereof
PE20231385A1 (es) 2020-09-17 2023-09-12 Janssen Pharmaceuticals Inc Composiciones de vacunas multivalentes y usos de las mismas
CN116888140A (zh) 2021-01-12 2023-10-13 杨森制药公司 FimH突变体、其组合物及其用途
JP2024514074A (ja) 2021-04-01 2024-03-28 ヤンセン ファーマシューティカルズ，インコーポレーテッド Ｅ．ｃｏｌｉ ｏ１８バイオコンジュゲートの産生
US20240180940A1 (en) * 2021-05-27 2024-06-06 Revelation Biosciences, Inc. Mpla compositions and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5068191A (en) * 1989-08-31 1991-11-26 The Biomembrane Institute Purified histo-blood group a glycosyltransferase and antibodies thereto
US5552141A (en) * 1991-10-30 1996-09-03 Ribi; Hans O. Polymeric immunological adjuvants
WO1994021292A1 (en) * 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a

Also Published As

Publication number Publication date
KR20010005882A (ko) 2001-01-15
PL336698A1 (en) 2000-07-03
CA2284586C (en) 2011-02-08
DE69826842T2 (de) 2005-11-24
KR100603884B1 (ko) 2006-07-24
WO1998043670A3 (en) 1998-12-30
DE69826842D1 (de) 2004-11-11
ES2227825T3 (es) 2005-04-01
CN1326564C (zh) 2007-07-18
HUP0001403A3 (en) 2003-05-28
CN1259052A (zh) 2000-07-05
AU6947398A (en) 1998-10-22
HK1026613A1 (en) 2000-12-22
BR9811262A (pt) 2000-10-17
JP2001526640A (ja) 2001-12-18
AU743114B2 (en) 2002-01-17
EP0971739A2 (de) 2000-01-19
NO994760D0 (no) 1999-09-30
NO994760L (no) 1999-11-26
PT971739E (pt) 2004-12-31
JP5019494B2 (ja) 2012-09-05
NZ338101A (en) 2002-03-28
WO1998043670A2 (en) 1998-10-08
EP0971739B1 (de) 2004-10-06
IL132126A (en) 2006-10-05
TR199902437T2 (xx) 2000-01-21
CA2284586A1 (en) 1998-10-08
HUP0001403A2 (hu) 2000-09-28
PL190237B1 (pl) 2005-11-30
CN1575815A (zh) 2005-02-09
IL132126A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
ATE278419T1 (de) Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a
ATE381344T1 (de) Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a
US6500453B2 (en) Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
CA1047921A (en) Liposomes used as adjuvants in vaccines
ES2277339T3 (es) Vacuna con adyuvante de aceite y metodo para su preparacion.
JPH09508349A (ja) 安定化オルトケイ酸含有調製物および生物学的調製物
GB2124618A (en) Aliphatic hydroxy amides
PE20000574A1 (es) Articulos, metodos y composiciones para limpiar productos agricolas y proteina animal comestible
HU195620B (en) Process for producing conjugates with immunogenic effect and built up from haptenes and muramylpeptides and pharmaceutics comprising these conjugates
RU2074192C1 (ru) Мурамилдипептидные производные, противогриппозная вакцина
FR2533827A1 (fr) Composition possedant des proprietes immunoregulatrices, notamment d'adjuvants immunologiques non specifiques, a base de muramylpeptide et d'un derive d'aluminium
US20080226709A1 (en) Phospholipid membrane preparation
CA1259750A (fr) Derives lipophiles de muramylpeptides ayant des proprietes d'activation des macrophages, compositions les contenant et procede pour les obtenir
DE69424447D1 (de) Verfahren zur herstellung von aminoxyd tenside enthaltenden festen zusammensetzungen
US20020031543A1 (en) Adjuvant comprising pulmonary surfactant
KR0178422B1 (ko) 한탄 바이러스의 펩타이드 항원을 함유하는 리포좀
KR0173366B1 (ko) B형 간염 바이러스의 펩타이드 항원을 함유하는 리포좀
JPH08183742A (ja) 経鼻ワクチンリポソーム
KR0173365B1 (ko) C형 간염 바이러스의 펩타이드 항원을 함유하는 리포좀
KR100189701B1 (ko) B형 간염 바이러스의 x 단밸직 유래의 펩타이드 항원을 함유하는 리포좀
JPH03287510A (ja) 化粧料
JPH0292996A (ja) アジュバントおよび脂質を含む複合体

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0971739

Country of ref document: EP